Globus Medical, Inc. $GMED Shares Sold by Vanguard Group Inc.

Vanguard Group Inc. trimmed its stake in Globus Medical, Inc. (NYSE:GMED) by 1.0% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 10,605,747 shares of the medical device company’s stock after selling 103,146 shares during the quarter. Vanguard Group Inc. owned approximately 0.08% of Globus Medical worth $607,391,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of the business. State of New Jersey Common Pension Fund D boosted its holdings in Globus Medical by 2.5% during the third quarter. State of New Jersey Common Pension Fund D now owns 39,035 shares of the medical device company’s stock worth $2,236,000 after buying an additional 943 shares in the last quarter. Conscious Wealth Investments LLC boosted its position in Globus Medical by 5.1% during the third quarter. Conscious Wealth Investments LLC now owns 49,052 shares of the medical device company’s stock worth $2,962,000 after purchasing an additional 2,364 shares during the period. HighTower Advisors LLC boosted its holdings in shares of Globus Medical by 4.6% during the 3rd quarter. HighTower Advisors LLC now owns 40,466 shares of the medical device company’s stock worth $2,317,000 after buying an additional 1,782 shares during the period. Illinois Municipal Retirement Fund raised its stake in shares of Globus Medical by 36.4% in the third quarter. Illinois Municipal Retirement Fund now owns 48,060 shares of the medical device company’s stock valued at $2,752,000 after purchasing an additional 12,823 shares in the last quarter. Finally, Caprock Group LLC bought a new stake in Globus Medical during the 3rd quarter worth approximately $621,000. Institutional investors own 95.16% of the company’s stock.

Globus Medical Stock Down 1.5%

Shares of NYSE GMED opened at $92.01 on Wednesday. Globus Medical, Inc. has a twelve month low of $51.79 and a twelve month high of $101.40. The business’s 50 day moving average price is $90.10 and its two-hundred day moving average price is $75.84. The company has a market cap of $12.31 billion, a PE ratio of 29.68, a price-to-earnings-growth ratio of 1.43 and a beta of 1.06.

Globus Medical (NYSE:GMED) last released its quarterly earnings data on Tuesday, February 24th. The medical device company reported $1.28 EPS for the quarter, topping analysts’ consensus estimates of $1.06 by $0.22. The firm had revenue of $826.42 million during the quarter, compared to analysts’ expectations of $803.29 million. Globus Medical had a net margin of 15.30% and a return on equity of 11.52%. The company’s revenue for the quarter was up 25.7% compared to the same quarter last year. During the same period in the previous year, the business posted $0.84 earnings per share. As a group, research analysts anticipate that Globus Medical, Inc. will post 3.44 EPS for the current fiscal year.

Wall Street Analyst Weigh In

GMED has been the subject of a number of analyst reports. Royal Bank Of Canada lifted their target price on shares of Globus Medical from $92.00 to $100.00 and gave the stock an “outperform” rating in a report on Wednesday, December 17th. Citigroup restated a “market perform” rating on shares of Globus Medical in a research report on Thursday, January 8th. Piper Sandler reissued an “overweight” rating and set a $115.00 price objective (up from $90.00) on shares of Globus Medical in a research report on Thursday, January 8th. Wall Street Zen raised Globus Medical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 3rd. Finally, Bank of America raised Globus Medical from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $65.00 to $91.00 in a research report on Friday, November 7th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, Globus Medical has a consensus rating of “Moderate Buy” and a consensus price target of $100.18.

Key Globus Medical News

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Q4 revenue and non‑GAAP EPS beat expectations — Worldwide net sales were $826.4M (+25.7% YoY) and non‑GAAP diluted EPS was $1.28, ahead of consensus; the quarter showed strong margin expansion. GlobeNewswire
• Positive Sentiment: 2026 guidance and upgraded EPS outlook — Management reaffirmed 2026 revenue guidance of $3.18–$3.22B and raised non‑GAAP EPS guidance to $4.40–$4.50, a signal of confidence in continued margin leverage. GlobeNewswire
• Positive Sentiment: Analyst support — Multiple analysts maintained or raised bullish ratings/targets after results (Morgan Stanley reiterated Buy, PT $100; Needham reiterated Buy and raised its PT to $114), which can fuel further buying. TipRanks – Morgan Stanley TipRanks – Needham
• Neutral Sentiment: Acquisition-driven growth — Management credits integration of Nevro (and NuVasive earlier) for a big portion of incremental sales and EPS; that supports scale but raises questions about organic momentum. QuiverQuant summary
• Negative Sentiment: GAAP vs. non‑GAAP and sustainability concerns — GAAP diluted EPS ($1.03) is below the non‑GAAP number and some third‑party reports noted mixed EPS comparisons versus certain estimates; investors may discount non‑GAAP gains driven by acquisitions and one‑time items. QuiverQuant – EPS detail
• Negative Sentiment: Insider selling & cash reduction — Recent filings show multiple insider sales and cash & cash equivalents fell to ~$526M from ~$784M year‑over‑year, which could concern some investors about cash deployment and insider conviction. QuiverQuant – insider/cash

Insider Activity at Globus Medical

In other news, Director Leslie V. Norwalk sold 2,000 shares of the business’s stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $101.10, for a total transaction of $202,200.00. Following the completion of the sale, the director owned 10,419 shares in the company, valued at $1,053,360.90. The trade was a 16.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Kyle Kline sold 18,542 shares of the company’s stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $90.00, for a total value of $1,668,780.00. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 34,136 shares of company stock worth $3,111,033. Insiders own 18.54% of the company’s stock.

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.